Literature DB >> 12697962

Selenium in breast cancer.

Juan-Bosco Lopez-Saez1, Avelino Senra-Varela, Lorenzo Pousa-Estevez.   

Abstract

AIM: Controversy surrounds the hypothetical relationship between low serum levels of selenium and reduced activity of selenium-dependent enzymes, such as glutathione peroxidase, and an increased risk of cancer in humans. This study investigated serum concentrations of selenium in women with and without breast cancer.
METHODS: In this case-control study, we compared serum concentrations of selenium in women with breast cancer (n = 200), healthy women (n = 100), and women with chronic diseases (n = 100). Patients with breast cancer were divided into premenopausal (n = 99) and postmenopausal subjects (n = 101).
RESULTS: Mean serum concentrations of selenium were 81.1 microg/l in women with breast cancer and 98.5 microg/l in women with non-tumoral disease (p < 0.001).
CONCLUSION: Alterations in serum concentrations of selenium in women with breast cancer appear to be a consequence, rather than a cause of cancer. In accordance with the hypothesis, the findings suggest that very low selenium status could be due to the nature of cancer. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697962     DOI: 10.1159/000069312

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  12 in total

1.  Serum total oxidant/antioxidant status and trace element levels in breast cancer patients.

Authors:  Jia-Fu Feng; Ling Lu; Ping Zeng; Yun-Hong Yang; Jun Luo; Yu-Wei Yang; Dong Wang
Journal:  Int J Clin Oncol       Date:  2011-10-05       Impact factor: 3.402

2.  Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines.

Authors:  Fabiola Rusolo; Francesca Capone; Raffaella Pasquale; Antonella Angiolillo; Giovanni Colonna; Giuseppe Castello; Maria Costantini; Susan Costantini
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

Review 3.  Dietary Trace Element Intake and Risk of Breast Cancer: A Mini Review.

Authors:  Sehar Iqbal; Inayat Ali
Journal:  Biol Trace Elem Res       Date:  2022-01-11       Impact factor: 4.081

4.  Synergic activity of selenium and probiotic bacterium Enterococcus faecium M-74 against selected mutagens in Salmonella assay.

Authors:  A Belicová; L Krizková; J Dobias; J Krajcovic; L Ebringer
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

5.  Selenium in the prevention of human cancers.

Authors:  Mikael Björnstedt; Aristi P Fernandes
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

6.  Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA.

Authors:  K Charalabopoulos; A Kotsalos; A Batistatou; A Charalabopoulos; P Vezyraki; D Peschos; V Kalfakakou; A Evangelou
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

7.  Association between dietary intake and seasonal variations in postmenopausal women.

Authors:  Asieh Mansour; Zeinab Ahadi; Mostafa Qorbani; Saeed Hosseini
Journal:  J Diabetes Metab Disord       Date:  2014-04-25

8.  Distribution of selenium and oxidative stress in breast tumor-bearing mice.

Authors:  Chih-Hung Guo; Simon Hsia; Pei-Chung Chen
Journal:  Nutrients       Date:  2013-02-20       Impact factor: 5.717

9.  Lipid peroxidation and glutathione peroxidase activity relationship in breast cancer depends on functional polymorphism of GPX1.

Authors:  Ewa Jablonska; Jolanta Gromadzinska; Beata Peplonska; Wojciech Fendler; Edyta Reszka; Magdalena B Krol; Edyta Wieczorek; Agnieszka Bukowska; Peter Gresner; Michal Galicki; Oskar Zambrano Quispe; Zbigniew Morawiec; Wojciech Wasowicz
Journal:  BMC Cancer       Date:  2015-10-07       Impact factor: 4.430

10.  Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer risk.

Authors:  Catherine Méplan; Lars Ove Dragsted; Gitte Ravn-Haren; Anne Tjønneland; Ulla Vogel; John Hesketh
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.